Nicole Giunio-Zorkin1, Glen Brown2. 1. , BSc, PharmD, ACPR is a Clinical Pharmacist with St Paul's Hospital, Vancouver, British Columbia. 2. , BSc(Pharm), PharmD, FCSHP, BCPS, BCCCP, is a Clinical Pharmacy Specialist in Critical Care with St Paul's Hospital, Vancouver, British Columbia. He is also an Associate Editor with the Canadian Journal of Hospital Pharmacy.
Abstract
BACKGROUND: Thrombocytopenia is a well-recognized adverse effect of linezolid; however, the frequency of this adverse effect during therapy has been variable across previous studies, and the associated risk factors are unclear. OBJECTIVES: To identify the real-life frequency of new-onset thrombocytopenia due to linezolid and to determine the associated risk factors. METHODS: A retrospective observational cohort study was conducted among consecutive inpatients at a tertiary care hospital who received linezolid for a minimum of 5 days between January 2013 and August 2017. Data were extracted from electronic medical records obtained from a hospital database. Thrombocytopenia was defined as platelet count less than 100 × 109/L or a 50% reduction from baseline (i.e., before linezolid initiation). Risk factors were identified by comparing the characteristics of patients who experienced the adverse effect during linezolid therapy with those of patients who did not experience the adverse effect. Continuous data were analyzed with the t test and categorical data with the χ2 test. RESULTS: A total of 102 patients were included (38 women, 64 men; overall mean age 50 years, standard deviation [SD] 21). The mean duration of linezolid therapy was 14 (SD 10) days. Thrombocytopenia occurred in 18 patients (17.6%). Risk factors for the development of thrombocytopenia included mean duration of therapy (22 [SD 18] days versus 12 [SD 7] days; p = 0.023), renal replacement therapy (17% versus 4%; p = 0.032), renal impairment (61% versus 32%; p = 0.021), and concomitant administration of unfractionated heparin (50% versus 21%; p = 0.013). CONCLUSIONS: The real-life frequency of new-onset of thrombocytopenia in patients receiving linezolid for a minimum of 5 days was 17.6%. Risk factors for linezolid-induced thrombocytopenia included prolonged duration of therapy, renal impairment, and concomitant unfractionated heparin.
BACKGROUND: Thrombocytopenia is a well-recognized adverse effect of linezolid; however, the frequency of this adverse effect during therapy has been variable across previous studies, and the associated risk factors are unclear. OBJECTIVES: To identify the real-life frequency of new-onset thrombocytopenia due to linezolid and to determine the associated risk factors. METHODS: A retrospective observational cohort study was conducted among consecutive inpatients at a tertiary care hospital who received linezolid for a minimum of 5 days between January 2013 and August 2017. Data were extracted from electronic medical records obtained from a hospital database. Thrombocytopenia was defined as platelet count less than 100 × 109/L or a 50% reduction from baseline (i.e., before linezolid initiation). Risk factors were identified by comparing the characteristics of patients who experienced the adverse effect during linezolid therapy with those of patients who did not experience the adverse effect. Continuous data were analyzed with the t test and categorical data with the χ2 test. RESULTS: A total of 102 patients were included (38 women, 64 men; overall mean age 50 years, standard deviation [SD] 21). The mean duration of linezolid therapy was 14 (SD 10) days. Thrombocytopenia occurred in 18 patients (17.6%). Risk factors for the development of thrombocytopenia included mean duration of therapy (22 [SD 18] days versus 12 [SD 7] days; p = 0.023), renal replacement therapy (17% versus 4%; p = 0.032), renal impairment (61% versus 32%; p = 0.021), and concomitant administration of unfractionated heparin (50% versus 21%; p = 0.013). CONCLUSIONS: The real-life frequency of new-onset of thrombocytopenia in patients receiving linezolid for a minimum of 5 days was 17.6%. Risk factors for linezolid-induced thrombocytopenia included prolonged duration of therapy, renal impairment, and concomitant unfractionated heparin.
Authors: Michael E Brier; Dennis J Stalker; George R Aronoff; Donald H Batts; Kristi K Ryan; Margaret O'Grady; Nancy K Hopkins; Gail L Jungbluth Journal: Antimicrob Agents Chemother Date: 2003-09 Impact factor: 5.191
Authors: Wendy B Bernstein; Richard F Trotta; James T Rector; Jeffery A Tjaden; Anthony J Barile Journal: Ann Pharmacother Date: 2003-04 Impact factor: 3.154
Authors: Monica V Mahoney; Lindsey M Childs-Kean; Parisa Khan; Christina G Rivera; Ryan W Stevens; Keenan L Ryan Journal: Curr Infect Dis Rep Date: 2021-11-09 Impact factor: 3.725